Lucid Diagnostics price target lowered to $2 from $2.50 at BTIG

BTIG lowered the firm’s price target on Lucid Diagnostics (LUCD) to $2 from $2.50 and keeps a Buy rating on the shares. The company turned in a solid Q4 volume beat, and for 2024, turned in 79% revenue growth, driven by 41% and 32% Y/Y growth in volumes and average selling prices respectively, the analyst tells investors in a research note, stating that the company is addressing a large unmet need with its minimally invasive EsoGuard test. BTIG adds that its price target cut reflects some dilution from Lucid’s recent financing.